![](https://www.biopharmadive.com/imgproxy/aH_D-JAk_0aqNS0u54ZcyMSAUnag9UewGKUlwu-KOIU/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTEwNTM0MzQxNjguanBn.webp)
FDA lifts hold on PTC Huntington’s disease trial
Dive Brief: PTC Therapeutics said Thursday it can resume a Phase 2 trial of its Huntington’s disease drug in the
Read MoreJuly 7, 2024
Dive Brief: PTC Therapeutics said Thursday it can resume a Phase 2 trial of its Huntington’s disease drug in the
Read MoreRoche has partnered with Ascidian Therapeutics to develop so-called “RNA exon editing” drugs, the latest foray by the Swiss pharmaceutical
Read MoreToday, a brief rundown of news from Belharra Therapeutics, AstraZeneca, Regenxbio and Tasyha Gene Therapies. Sanofi will work with biotechnology
Read MoreDive Brief: Intra-Cellular Therapies plans to seek clearance to sell its medicine Caplyta for patients with depression after a second-late
Read MoreDive Brief: The Food and Drug Administration on Monday approved a new vaccine from Merck & Co. that protects against
Read MoreDive Brief: An experimental pill developed by Takeda to treat the rare epilepsies Dravet and Lennox-Gastaut syndromes missed the main
Read MoreAbbVie is securing its place in an emerging gastrointestinal disease drug field, paying China-based FutureGen Biopharmaceutical $150 million in immediate
Read MoreDive Brief: Telix, an Australia-based developer of radiopharmaceutical drugs for cancer, has canceled plans to raise roughly $200 million via
Read MoreDive Brief: Moderna said its next-generation COVID-19 vaccine succeeded in a Phase 3 study, offering increased effectiveness for adults. The
Read MoreThe Supreme Court on Thursday unanimously ruled an anti-abortion group contesting the Food and Drug Administration’s approval of the abortion
Read More